Kiniksa Pharmaceuticals Ltd at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Hi. Good morning, everyone. We will continue with the next session, which is Kiniksa Pharmaceuticals. Please note that this session will be audio only. And with that, I'm pleased to turn it over to CEO, Sanj Patel, who will kick it off with some introductory remarks. Sanj?
Thanks, Paul. Good morning, and thanks, obviously, to Goldman Sachs for hosting us today. With me on the call are John Paolini, our Chief Medical Officer; Ross Moat, the ARCALYST General Manager and Head of Commercial; and Mark Ragosa, who's our Chief Financial Officer.
As always, please note that we will be making forward-looking statements today that are subject to both risks and uncertainties. A review of these statements and risk factors are found under the heading of Risk Factors in our SEC filings.
We are happy to have the opportunity today to discuss our recent approval and launch of ARCALYST in recurrent
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |